View clinical trials related to Breast Cancer.Filter by:
Some HER-2 breast cancer patients do not respond or build resistance to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug. It has not yet been approved for use. DS-8201a may slow down tumor growth. This might improve outcomes for these patients.
Patients will be randomly assigned to one of two groups: the group exposed to NS, or the standard care group exposed to supportive dialogue. Patients assigned to the former group will be exposed to continuous NS throughout the CNB procedure.
Women with genitourinary syndrome of menopause, with breast or endometrial cancer are randomized to either laser treatment og sham treatment for 3 months. The randomization is stratified for estrogen treatment. The effect is evaluated by questionnaire, histology and microbiology swaps
This pilot study evaluates the use of high-intensity focused ultrasound (HIFU) combined with pembrolizumab in patients with metastatic breast cancer. One-half of participants will be randomized to receive the first dose of pembrolizumab after HIFU and one-half of participants will be randomized to receive their first dose of pembrolizumab before HIFU.
Background: Nausea and vomiting (emesis) is a common known problem for patients with cancer who are undergoing chemotherapy. Emesis affects both the patient´s quality of life and induces high costs within the health-care system. Acupuncture is an upcoming treatment for emesis, despite lacking evidence for effects beside non-specific effects since few credibly sham-controlled studies previously have been conducted. The therapist's care and communication during the needling sessions may induce non-specific effects, potentially driven by the patient's expectations. It is not known if the type of communication, in terms of how positive the therapist communicates regarding expected effects, affects the effect of acupuncture for emesis. Aims: The aim of this study is to investigate if chemotherapy-induced nausea, vomiting, and quality of life differ between patients who receive a) standard care including antiemetics, b) standard care plus sham acupuncture or c) standard treatment plus genuine acupuncture. The aim is also to investigate if chemotherapy-induced nausea, vomiting, and quality of life differ between patients who receive the above mentioned standard care, sham acupuncture, or genuine acupuncture by a therapist who emphasizes the positive expected outcomes of the treatment, compared to a therapist who communicates neutral regarding the outcomes. Procedure: The eligible patients will be randomized to A) standard care, including antiemetics or to B) standard treatment plus sham acupuncture or C) standard treatment plus genuine acupuncture. Within the three groups, the patients are randomized to receive either neutral or positive communication with the therapist during the treatment. Outcome measures: Nausea and vomiting are documented in questionnaires and in a diary, measured with Visual Analogue Scales. Well-being, activity level and quality of life are measured with questionnaires.
Prospective, open label, multicenter, randomized phase III study, comparing two strategies as first chemotherapy-based treatment for locally advanced or metastatic luminal breast cancer. - Arm A: concomitant chemotherapy plus an aromatase inhibitor (AI); the AI must continue until disease progression or toxicity or patient refusal; chemotherapy may be stopped after achievement of maximum response (generally after at least about 3-6 months of treatment) or in case of toxicity or patient refusal. - Arm B: chemotherapy followed by an AI at the time of progression to chemotherapy (if an endocrine therapy is deemed indicated by the treating physician) or as maintenance therapy after achieving maximum response to chemotherapy (generally after at least about 3-6 months of treatment) or after stopping chemotherapy for toxicity or patient refusal.
This a multicenter, open-label, phase II clinical trial to assess the efficacy of pembrolizumab in combination with eribulin in female patients older than 18 years old with hormone receptor-(HR)positive/HER2-negative metastatic breast cancer (MBC) previously treated with at least one, but not more than two, prior chemotherapeutic regimens for treatment of locally recurrent and/or metastatic disease. Prior therapy must have included an anthracycline and a taxane and prior anti-hormonal therapy is mandatory. The number of patients to be included is 44 patients at 11 sites. All eligible patients will be treated with MK3475 (pembrolizumab) 200 mg on day 1 of each 21-day cycle and eribulin 1.23 mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) on days 1 and 8 of every 21-day cycle.
This is an exploratory interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for four weeks.
Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers
Breast-cancer related lymphoedema (BCRL) is a common phenomenon. Early diagnosis and treatment is very important to alter the normal progression of this disease. A threshold (>= 3% volume change) that recognizes subclinical lymphedema is promoted. When the lymphedema is diagnosed late, options for treatment are diminished as fibrous tissue is formed. Preoperative investigation with near-infrared fluorescence lymphography can show an abnormality. Even if a linear transport is visualized, velocity of the transport can be diminished or a different pathway than normal can be visualized. Such an extensive evaluation has not been performed yet. This lymphofluoroscopy gives an opportunity to detect lymphedema earlier than clinically visible (subclinical). The investigators hypothesize that the evolution of lymphedema can be altered if treatment is started in the subclinical phase.